<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12757604</article-id><article-id pub-id-type="pmcid-ver">PMC12757604.1</article-id><article-id pub-id-type="pmcaid">12757604</article-id><article-id pub-id-type="pmcaiid">12757604</article-id><article-id pub-id-type="pmid">41487526</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1672774</article-id><article-id pub-id-type="publisher-id">1672774</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Multilocus inherited neoplasia allele syndrome (MINAS) in a Turkish cohort: molecular insights and clinical relevance for precision oncology</article-title><alt-title alt-title-type="left-running-head">Bahsi et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2025.1672774" ext-link-type="uri">10.3389/fphar.2025.1672774</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bahsi</surname><given-names initials="T">Taha</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3136789"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seyhan</surname><given-names initials="S">Serhat</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Helvaci</surname><given-names initials="K">Kaan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Demirci</surname><given-names initials="U">Umut</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bilgetekin</surname><given-names initials="I">Irem</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bayram</surname><given-names initials="S">Selami</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozturk</surname><given-names initials="MA">Mehmet Akif</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aydogan</surname><given-names initials="F">Fatih</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Keskin</surname><given-names initials="S">Serkan</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pilanci</surname><given-names initials="K">Kezban</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sener</surname><given-names initials="N">Nur</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tatl&#305;</surname><given-names initials="M">Murat</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Harputluoglu</surname><given-names initials="H">Hakan</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Namal</surname><given-names initials="E">Esat</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kargi</surname><given-names initials="A">Aysegul</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uysal</surname><given-names initials="M">Mukremin</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ilhan</surname><given-names initials="M">Mahmut</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Erol</surname><given-names initials="C">Cihan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kose</surname><given-names initials="N">Naziyet</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Okutur</surname><given-names initials="K">Kerem</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karaca</surname><given-names initials="H">Halit</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dogan</surname><given-names initials="E">Erkan</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Berk</surname><given-names initials="V">Veli</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ekinci</surname><given-names initials="AS">Ahmet Siyar</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozdogan</surname><given-names initials="M">Mustafa</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Department of Medical Genetics, &#220;sk&#252;dar University</institution>, <city>&#220;sk&#252;dar</city>, <country country="TR">T&#252;rkiye</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Memorial Health Group</institution>, <city>Ankara</city>, <country country="TR">T&#252;rkiye</country>
</aff><aff id="aff3">
<label>3</label>
<institution>Department of Medical Genetics, MedRoyal Genetic Disease Evaluation Center, Memorial Healthcare Group</institution>, <city>Istanbul</city>, <country country="TR">T&#252;rkiye</country>
</aff><aff id="aff4">
<label>4</label>
<institution>Memorial Health Group Antalya</institution>, <city>Antalya</city>, <country country="TR">T&#252;rkiye</country>
</aff><aff id="aff5">
<label>5</label>
<institution>Memorial Health Group Istanbul</institution>, <city>Istanbul</city>, <country country="TR">T&#252;rkiye</country>
</aff><aff id="aff6">
<label>6</label>
<institution>Department of Medical Genetics, Memorial Bahcelievler Hospital</institution>, <city>Istanbul</city>, <country country="TR">T&#252;rkiye</country>
</aff><aff id="aff7">
<label>7</label>
<institution>Memorial Health Group</institution>, <city>Istanbul</city>, <country country="TR">T&#252;rkiye</country>
</aff><author-notes><corresp id="c001"><label>*</label>Correspondence: Taha Bahsi, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tahabahsi@yahoo.com">tahabahsi@yahoo.com</email></corresp></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-12-19"><day>19</day><month>12</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480654</issue-id><elocation-id>1672774</elocation-id><history><date date-type="received"><day>24</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>03</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-05 09:25:15.180"><day>05</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Bahsi, Seyhan, Helvaci, Demirci, Bilgetekin, Bayram, Ozturk, Aydogan, Keskin, Pilanci, Sener, Tatl&#305;, Harputluoglu, Namal, Kargi, Uysal, Ilhan, Erol, Kose, Okutur, Karaca, Dogan, Berk, Ekinci and Ozdogan.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Bahsi, Seyhan, Helvaci, Demirci, Bilgetekin, Bayram, Ozturk, Aydogan, Keskin, Pilanci, Sener, Tatl&#305;, Harputluoglu, Namal, Kargi, Uysal, Ilhan, Erol, Kose, Okutur, Karaca, Dogan, Berk, Ekinci and Ozdogan</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-12-19">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-16-1672774.pdf"/><abstract><sec><title>Background</title><p>Multilocus Inherited Neoplasia Allele Syndrome (MINAS) describes individuals who harbor pathogenic or likely pathogenic (LP/P) germline variants in two or more distinct cancer predisposition genes. With the broader implementation of next-generation sequencing (NGS) and multigene panel testing, MINAS has been increasingly recognized.</p></sec><sec><title>Methods</title><p>We retrospectively evaluated 655 Turkish patients referred for hereditary cancer testing using two validated NGS panels. MINAS was defined as the presence of LP/P variants in at least two different genes.</p></sec><sec><title>Results</title><p>14 patients (2.13%) met the criteria for MINAS. An additional 156 patients (23.8%) had single-gene LP/P variants. MINAS cases accounted for 8.2% of mutation-positive individuals. These patients showed diverse tumor types. Common gene combinations included <italic toggle="yes">BRCA1+MUTYH</italic> and <italic toggle="yes">CHEK2+PALB2</italic>.</p></sec><sec><title>Conclusion</title><p>This is the first MINAS-focused analysis from a Turkish cohort. Although uncommon, MINAS represents a significant subset of genetically high-risk individuals requiring tailored clinical management.</p></sec></abstract><kwd-group><kwd>MINAS</kwd><kwd>germline variants</kwd><kwd>multigene panel</kwd><kwd>BRCA</kwd><kwd>Turkish cohort</kwd><kwd>hereditary cancer</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="15"/><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pharmacology of Anti-Cancer Drugs</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Hereditary cancer syndromes account for approximately 5%&#8211;10% of all malignancies and have long been characterized by monogenic inheritance patterns, wherein a pathogenic variant in a single high-penetrance gene (e.g., <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">TP53</italic>) confers a significantly elevated lifetime risk of specific cancers. However, the increasing use of next-generation sequencing (NGS) and the advent of comprehensive multigene panel testing have uncovered a more complex genetic architecture of cancer predisposition than previously understood (<xref rid="B5" ref-type="bibr">Ates et al., 2022</xref>; <xref rid="B1" ref-type="bibr">Couch et al., 2017</xref>). A growing subset of individuals have been found to harbor pathogenic or likely pathogenic (LP/P) germline variants in more than one cancer susceptibility gene&#8212;a phenomenon now referred to as Multilocus Inherited Neoplasia Allele Syndrome (MINAS).</p><p>MINAS was first described systematically by Schrader et al., in 2016, who reported individuals carrying LP/P mutations in two or more distinct cancer-associated genes. Variants of uncertain significance (VUS) are not counted toward this definition. Subsequent studies have demonstrated that MINAS is not an exceedingly rare occurrence, with reported prevalence ranging from 0.5% to 3% of individuals undergoing hereditary cancer testing (<xref rid="B13" ref-type="bibr">Whitworth et al., 2016</xref>; <xref rid="B15" ref-type="bibr">Agaoglu et al., 2024</xref>). These findings have profound implications for clinical practice, including risk assessment, genetic counseling (<xref rid="B4" ref-type="bibr">Hampel et al., 2015</xref>), and individualized cancer surveillance and prevention strategies.</p><p>Patients with MINAS may exhibit unusual clinical phenotypes, including early age of onset, multiple primary malignancies, or tumors that do not strictly correlate with the phenotype predicted by any one of the individual gene mutations. Additionally, the coexistence of mutations in genes that function within distinct DNA damage response pathways&#8212;such as homologous recombination repair (e.g., <italic toggle="yes">BRCA1/2</italic>) and mismatch repair (e.g., <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>)&#8212;may contribute to unique tumor biology and potential therapeutic vulnerabilities (<xref rid="B10" ref-type="bibr">El Tekle et al., 2021</xref>). The clinical implications of harboring multiple LP/P variants are still under investigation, and few evidence-based guidelines currently address the optimal management of these patients.</p><p>Moreover, MINAS poses significant challenges to genetic counseling. Family histories may appear discordant, with different relatives inheriting distinct variants, complicating risk prediction and cascade testing strategies (<xref rid="B11" ref-type="bibr">Bednar et al., 2024</xref>). These complexities are further compounded by limited data on penetrance, expressivity, and the interaction between co-inherited mutations, particularly in underrepresented populations.</p><p>Despite increasing recognition of MINAS in the literature, data from non-Western populations remain sparse. Most existing studies originate from North America and Western Europe, leading to a gap in the global understanding of MINAS prevalence and spectrum. Populations with unique genetic backgrounds, such as those in the Middle East and Mediterranean regions, may harbor distinct mutation profiles and gene-gene interactions, underscoring the need for regional studies.</p><p>In this context, we present the first comprehensive analysis of MINAS in a Turkish hereditary cancer cohort. Using validated multigene panels, we systematically evaluated 655 individuals for germline LP/P variants and identified those harboring multilocus alterations. Our objectives were to determine the prevalence and spectrum of MINAS in this population, describe the associated tumor phenotypes, and compare our findings with the existing global literature. By expanding the epidemiological and clinical landscape of MINAS, our study contributes to the development of informed guidelines and lays the foundation for future research into the biological and clinical consequences of multilocus inherited cancer risk.</p><p>In large cohorts undergoing germline testing, MINAS prevalence ranges between 0.5% and 3% (<xref rid="B14" ref-type="bibr">Tung et al., 2016</xref>). These individuals may exhibit complex phenotypes, multiple primary tumors, or early-onset disease. The impact of multiple mutations, particularly across distinct repair pathways like homologous recombination and mismatch repair, remains to be fully elucidated (<xref rid="B2" ref-type="bibr">Drost and Clevers, 2018</xref>).</p><p>This study presents the first detailed evaluation of MINAS in a Turkish population. We analyzed the frequency, gene combinations, and cancer phenotypes of MINAS individuals within a 655-patient cohort and contextualized these findings in the broader spectrum of hereditary cancer genetics.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><sec id="s2-1"><title>Study population and ethical approval</title><p>This retrospective study included 655 consecutive patients who were referred for germline hereditary cancer testing between February 2024 and May 2025&#160;at tertiary medical genetics clinics within the Memorial Healthcare Group, Turkey. Eligible individuals had a personal and/or family history suggestive of hereditary cancer syndromes, including early-onset malignancies, multiple primary tumors, and/or a significant family history of cancer in first- or second-degree relatives. Patients with insufficient clinical data or inadequate DNA quality were excluded.</p><p>All procedures were conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Antalya Memorial Hospital Ethics Committee (Decision No: 06, Date: 18.06.2025). Since all data were de-identified and used retrospectively, individual informed consent was not required according to institutional policy.</p></sec><sec id="s2-2"><title>DNA isolation and library preparation</title><p>Peripheral blood samples were collected in EDTA tubes, and genomic DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen) and the Promega Maxwell RSC Blood DNA Kit according to the manufacturers&#8217; protocols. DNA quantity and purity were assessed using NanoDrop spectrophotometry and Qubit fluorometric quantification.</p></sec><sec id="s2-3"><title>Next-generation sequencing and bioinformatics</title><p>Sequencing data were processed using vendor-specific pipelines. Raw reads were subjected to base calling, demultiplexing, and adapter trimming. Sequences were aligned to the human reference genome (GRCh37/hg19) using BWA-MEM. Sequencing was performed on the Illumina NextSeq 2000 platform following the manufacturer&#8217;s standard workflow. Sophia Genetics Hereditary Cancer Solutions Panel was used with cancer predisposition genes i<italic toggle="yes">ATM, APC, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, DDB2, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCC, FH, FLCN, GALNT12, HDAC2, HOXB13, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PMS2, PMS2CL, POLD1, POLE, POLH, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, SMAD4, STK11, TP53, TSC1, TSC2, VHL, WT1, XPA, XPC</italic>. Libraries passing initial quality control were loaded onto the NextSeq 2000 flow cell using the integrated loading system. Cluster generation and sequencing were carried out on-board with a paired-end read configuration (2 &#215; 150&#160;bp). Primary data processing, including base calling and quality scoring, was performed in real time using Sophia DDM&#8482; cloud platform. Raw BCL files were subsequently demultiplexed and converted to FASTQ format for downstream analysis. Also other targeted sequencing was performed using the Twist Bioscience Hereditary Cancer Panel, which includes a comprehensive set of cancer predisposition genes <italic toggle="yes">ABL1, ABRAXAS1, AKT1, ALK, ALX1, APC, AR, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBL, CDH1, CDK4, CDKN2A, CEBPA, CHEK2, CSF1R, CSF3R, CTNNB1, DICER1, DIS3L2, DNM2, DNMT3A, EGFR, ELA2, ELANE, EPCAM, ERBB2, ERBB4, ESR1, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FGFR1, FGFR2, FGFR3, FH, FLCN, FLT3, GALNT12, GFI1, GNA11, GNAQ, GNAS, HAX1, HMMR, HNF1A, HNF1B, HOXB13, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MC1R, MEN1, MET, MITF, MLH1, MLH3, MPL, MRE11, MRE11A, MSH2, MSH3, MSH6, MUTYH, MUTYH, NBN, NF1, NOTCH1, NPM1, NQO2, NRAS, NTHL1, PALB2, PDGFRA, PHB, PIK3CA, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PRSS1, PTCH1, PTEN, PTPN11, RAD50, RAD51, RAD51C, RAD51D, RAD54L, RB1, RB1CC1, RECQL, RET, RNF43, RRAS2, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SF3B1, SLC22A1L, SLX4, SMAD4, SMARCA4, SMARCB1, SMO, SRC, SRSF2, STK11, TET2, TGFBR2, TP53, TSC1, TSC2, U2AF1, USB1, VHL, WAS, WT1, XRCC2, XRCC3</italic>. Library preparation was carried out according to the manufacturer&#8217;s protocol, followed by circularization and generation of DNA nanoballs (DNBs). Sequencing was conducted on the MGI DNBSEQ-G400 platform using paired-end reads (2 &#215; 150&#160;bp) with combinatorial Probe-Anchor Synthesis (cPAS) chemistry. Raw data were processed through MGI&#8217;s standard pipeline for base calling, demultiplexing, and adapter trimming. Reads were aligned to the human reference genome (GRCh37/hg19) using BWA-MEM. Variant calling and downstream analysis were performed using the GenomizeSeq clinical bioinformatics pipeline.</p><p>Single nucleotide variants (SNVs) and small insertions/deletions (indels) were annotated and classified according to the 2015 ACMG-AMP guidelines. Copy number variants (CNVs) were evaluated using depth-of-coverage&#8211;based algorithms embedded within the GenomizeSeq platform. All pathogenic (P) and likely pathogenic (LP) variants, along with variants of uncertain significance (VUS), were reviewed and manually curated in a clinical context. The final report included detailed variant annotation, zygosity, ACMG classification, associated phenotypes, and clinical actionability, if applicable.</p><p>Quality control thresholds included minimum coverage of &#8805;100&#215; and variant allele frequency (VAF) &#8805;0.2 for heterozygous variants.</p></sec><sec id="s2-4"><title>Variant annotation and classification</title><p>Variants were annotated using the Genomize Seq Platform and classified following the ACMG/AMP 2015 guidelines. Classifications were cross-referenced with ClinVar, gnomAD, HGMD Professional, and LOVD databases. Only pathogenic or likely pathogenic (LP/P) variants were included in the final analysis. Variants of uncertain significance (VUS) were excluded. Zygosity was determined by examining VAF and sequencing reads.</p></sec><sec id="s2-5"><title>Definition of MINAS and clinical data collection</title><p>Multilocus Inherited Neoplasia Allele Syndrome (MINAS) was defined as the presence of LP/P germline variants in &#8805;2 distinct cancer predisposition genes in the same individual. Compound heterozygous or homozygous variants in the same gene (e.g., biallelic <italic toggle="yes">MUTYH</italic>) were not classified as MINAS unless accompanied by a second LP/P variant in a different gene.</p><p>Clinical data including tumor type, age at diagnosis, and family history were retrospectively extracted from electronic medical records. Where available, pedigree charts and pathology reports were reviewed by board-certified clinical geneticists. Tumor phenotype&#8211;genotype concordance was assessed using NCCN and ESMO guidelines.</p></sec><sec id="s2-6"><title>Statistical analysis</title><p>Descriptive statistics were used to report the frequency of MINAS cases and associated gene combinations. Categorical variables were expressed as counts and percentages, and continuous variables as medians with interquartile ranges (IQR). Comparisons between groups (e.g., MINAS vs. non-MINAS) were conducted using Fisher&#8217;s exact test for categorical variables and the Mann&#8211;Whitney U test for continuous variables. A p-value &lt;0.05 was considered statistically significant. All analyses were conducted using R version 4.2.2.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>A total of 655 patients underwent germline genetic testing using either the Twist and Sophia hereditary cancer panels. Of these, 170 individuals (26%) were found to carry at least one pathogenic or likely pathogenic (LP/P) variant. Among mutation-positive patients, 156 (23.8% of total) had LP/P variants in a single gene, while 14 patients (2.13% of the cohort) met the criteria for MINAS, defined as the presence of LP/P variants in two or more distinct cancer predisposition genes. Consequently, MINAS accounted for 8.2% of the mutation-positive group (14/170) (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Distribution of LP/P variants in the MINAS and non-MINAS subgroups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1672774-g001.jpg"><alt-text content-type="machine-generated">Pie chart showing genetic variants. "No LP/P Variant" is 74.0% (yellow), "Single Gene LP/P" is 23.8% (orange), and "MINAS" is 2.2% (red). Total numbers: 485 in "No LP/P", 156 in "Single Gene LP/P", and 14 in "MINAS".</alt-text></graphic></fig><sec id="s3-1"><title>Clinically significant mutation frequency in non-MINAS cohort</title><p>This bar graph (<xref rid="F2" ref-type="fig">Figure 2</xref>) illustrates the frequency of clinically significant variants (Pathogenic, Likely Pathogenic, and Risk Factor variants) across genes in the non-MINAS cohort. The data was extracted from hereditary cancer panel testing results and reflects mutation burden distribution among relevant cancer predisposition genes. Only variants explicitly classified as pathogenic, likely pathogenic, or noted as a risk factor were included.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Gene-wise distribution of pathogenic and likely pathogenic variants in non-MINAS patients (bar chart).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1672774-g002.jpg"><alt-text content-type="machine-generated">Bar chart displaying mutation counts for various genes. BRCA2, BRCA1, ATM, and CHEK2 show the highest mutation counts, exceeding twenty. Other genes like FANCC, MLH1, and FANCA exhibit lower mutation counts, around five.</alt-text></graphic></fig><p>When stratified by tumor type, the most common cancer phenotype among MINAS patients was breast cancer, observed in 5 out of 14 cases (36%). This was followed by colorectal cancer in 2 patients, gastric cancer in 2 patients (14%), ovarian cancer in 1 patient (7%), endometrial cancer in 1 patient (7%), thyroid malignant neoplasm in 1 patient (7%), meningioma in 1 patient (7%) and co-occurrence of breast and pancreatic cancer in 1 patient (<xref rid="F3" ref-type="fig">Figure 3</xref>). Notably, some patients exhibited phenotypic features consistent with both mutated genes, whereas others presented with tumors typically associated with only one of the implicated genes.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Tumor type distribution among patients with MINAS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1672774-g003.jpg"><alt-text content-type="machine-generated">Bar chart displaying the number of patients with different cancer types. Breast cancer has the highest with five patients. Colorectal and gastric cancers have two patients each. Endometrial, breast and pancreatic, ovarian, thyroid malignancy, and meningioma each have one patient.</alt-text></graphic></fig><p>Analysis of the genetic findings in MINAS cases revealed that the most frequently involved genes were <italic toggle="yes">BRCA1, BRCA2, MUTYH, CHEK2, PALB2,</italic> and <italic toggle="yes">MSH6.</italic> Gene combinations observed more than once included <italic toggle="yes">BRCA1+MUTYH</italic> and <italic toggle="yes">CHEK2+PALB2</italic>. Importantly, all patients with co-occurring mutations had variants interpreted as LP or P according to ACMG guidelines, supported by ClinVar classification.</p><p>In terms of variant type, the majority were frameshift mutations followed by missense, nonsense and splice-site variants. The zygosity status was predominantly heterozygous for all detected variants, consistent with dominant inheritance patterns typical of high-risk cancer susceptibility genes. No biallelic or homozygous configurations were included in the MINAS categorization.</p><p>Among all LP/P variant carriers (n = 170), the presence of multiple mutations (MINAS) was significantly less frequent than single-gene alterations, but their clinical implications may be disproportionately impactful due to potential synergistic or additive effects on tumorigenesis. Detailed clinical and genetic characteristics of each MINAS patient are provided in <xref rid="T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Clinical and genetic characteristics of patients with MINAS.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Case</th><th align="center" rowspan="1" colspan="1">Sex</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Clinical diagnosis</th><th align="center" rowspan="1" colspan="1">Gene/Transcript</th><th align="center" rowspan="1" colspan="1">Variant/Protein change</th><th align="center" rowspan="1" colspan="1">Zygosity</th><th align="center" rowspan="1" colspan="1">Classification</th><th align="center" rowspan="1" colspan="1">Inheritance</th><th align="center" rowspan="1" colspan="1">Gene&#8211;Disease validity</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" colspan="1">1</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">61</td><td rowspan="2" align="left" colspan="1">Ovarian cancer</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">BRCA1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_007294.3">NM_007294.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.5266dup &gt; G p.(Gln1756Profs*74)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (HBOC)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ERCC3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000122.1">NM_000122.1</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1421dup p.(Asp474Glufs*2)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Moderate (Xeroderma pigmentosum; DNA repair; cancer risk evolving)</td></tr><tr><td rowspan="2" align="left" colspan="1">2</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">49</td><td rowspan="2" align="left" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">BRCA1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_007294.3">NM_007294.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1504_1508del p.(Leu502Ala fs*)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MUTYH (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001048171.1">NM_001048171.1</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.760C&gt;T p.(Gln254*)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Definitive (biallelic CRC); Limited (monoallelic)</td></tr><tr><td rowspan="2" align="left" colspan="1">3</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">39</td><td rowspan="2" align="left" colspan="1">Breast + pancreatic ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">BRCA1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_007294.3">NM_007294.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.4986 + 6T&gt;C p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">PALB2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_024675.3">NM_024675.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.173del p.(LeuCysfs*10)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (breast/pancreatic cancer)</td></tr><tr><td rowspan="2" align="left" colspan="1">4</td><td rowspan="2" align="left" colspan="1">M</td><td rowspan="2" align="left" colspan="1">71</td><td rowspan="2" align="left" colspan="1">Thyroid malignant neoplasm</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">CHEK2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001005735.1">NM_001005735.1</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.721 + 3A&gt;T p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Strong/Moderate (breast, thyroid, CRC risk)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MSH3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002439.4">NM_002439.4</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.2254-1_2257delinsTAC p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Limited/Moderate (biallelic CRC)</td></tr><tr><td rowspan="2" align="left" colspan="1">5</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">52</td><td rowspan="2" align="left" colspan="1">Breast cancer</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NTHL1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002528">NM_002528</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.244C&gt;T p.(Gln82Ter)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Definitive (biallelic CRC); Limited (monoallelic)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">JAK3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000215">NM_000215</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1744C&gt;T p.(Arg582Trp)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Limited (hematological malignancies, evolving)</td></tr><tr><td rowspan="2" align="left" colspan="1">6</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">39</td><td rowspan="2" align="left" colspan="1">Endometrial ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MSH2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000251">NM_000251</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1276 + 1G&gt;T p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (Lynch syndrome)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">RAD51C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_058216">NM_058216</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.706&#8211;2A&gt;G p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (hereditary breast/ovarian cancer)</td></tr><tr><td rowspan="2" align="left" colspan="1">7</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">49</td><td align="left" rowspan="1" colspan="1">Breast ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">FANCM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_020937.4">NM_020937.4</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.5101C&gt;T p.(Gln1701Ter)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Moderate (biallelic FA; monoallelic breast ca risk evolving)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">RAD54L (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003579.4">NM_003579.4</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.475G&gt;T p.(Glu159Ter)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Limited (DNA repair; cancer risk evolving)</td></tr><tr><td rowspan="2" align="left" colspan="1">8</td><td rowspan="2" align="left" colspan="1">M</td><td rowspan="2" align="left" colspan="1">28</td><td rowspan="2" align="left" colspan="1">Colorectal ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MLH1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000249.3">NM_000249.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.2073dup p.(Ser692IlefsTer2)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (Lynch syndrome)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">CHEK2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001005735.2">NM_001005735.2</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.190G&gt;A p.(Glu64Lys)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Strong/Moderate</td></tr><tr><td rowspan="2" align="left" colspan="1">9</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">48</td><td rowspan="2" align="left" colspan="1">Breast ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NTHL1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002528.7">NM_002528.7</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.244C&gt;T p.(Gln82Ter)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Definitive (biallelic); Limited (monoallelic)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">PPM1D (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003620.4">NM_003620.4</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.185_186del p.(Glu62GlyfsTer27)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Moderate (therapy-related clonal hematopoiesis, evolving)</td></tr><tr><td rowspan="2" align="left" colspan="1">10</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">39</td><td rowspan="2" align="center" colspan="1">Breast ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NF1 (NM_0010424923)</italic>
</td><td align="left" rowspan="1" colspan="1">c.5268 + 5G&gt;T p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (Neurofibromatosis type 1, breast ca risk)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MUTYH (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_012222.2">NM_012222.2</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1178G&gt;A p.(Gly393Asp)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Definitive (biallelic CRC); Limited (monoallelic)</td></tr><tr><td rowspan="2" align="left" colspan="1">11</td><td rowspan="2" align="left" colspan="1">M</td><td rowspan="2" align="left" colspan="1">57</td><td rowspan="2" align="left" colspan="1">Gastric ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MSH2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000251.3">NM_000251.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1204C&gt;T p.(Gln402Ter)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive (Lynch)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">FANCA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000135.4">NM_000135.4</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.4124_4125del p.(Thr1375SerfsTer49)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Definitive (biallelic FA); Limited (monoallelic cancer risk evolving)</td></tr><tr><td rowspan="2" align="left" colspan="1">12</td><td rowspan="2" align="left" colspan="1">M</td><td rowspan="2" align="left" colspan="1">28</td><td rowspan="2" align="left" colspan="1">Colorectal ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ATM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000051.3">NM_000051.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.5762 + 1G&gt;T p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive/Strong (breast, pancreatic, CRC)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">FANCC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000136.3">NM_000136.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.521 + 1G&gt;A p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AR</td><td align="left" rowspan="1" colspan="1">Definitive (biallelic FA); Limited (monoallelic)</td></tr><tr><td rowspan="2" align="left" colspan="1">13</td><td rowspan="2" align="left" colspan="1">M</td><td rowspan="2" align="left" colspan="1">67</td><td rowspan="2" align="left" colspan="1">Gastric ca</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MSH2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000251.3">NM_000251.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1667T&gt;C p.(Leu556Ser)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">PMS2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000535.7">NM_000535.7</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1012C&gt;T p.(Pro338Ser)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Likely pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Definitive</td></tr><tr><td rowspan="2" align="left" colspan="1">14</td><td rowspan="2" align="left" colspan="1">F</td><td rowspan="2" align="left" colspan="1">34</td><td rowspan="2" align="left" colspan="1">Meningioma</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ATM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000051.3">NM_000051.3</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.4909 + 1G&gt;A p.(?)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Strong/Definitive</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">MITF (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001354604.2">NM_001354604.2</ext-link>)</italic>
</td><td align="left" rowspan="1" colspan="1">c.1273G&gt;A p.(Glu425Lys)</td><td align="left" rowspan="1" colspan="1">Het</td><td align="left" rowspan="1" colspan="1">Pathogenic</td><td align="left" rowspan="1" colspan="1">AD</td><td align="left" rowspan="1" colspan="1">Moderate (melanoma, renal cell carcinoma; evolving in brain tumors)</td></tr></tbody></table></table-wrap><p>These findings reinforce the diagnostic and clinical value of comprehensive multigene panel testing, especially in genetically heterogeneous populations, and suggest that MINAS may be underrecognized in standard single-gene approaches. Tumor types in MINAS patients included breast cancer (n = 5), colorectal cancer (n = 2), gastric cancer (n = 2), endometrial cancer (n = 1), co-occurrence of breast and pancreatic cancer (n = 1), ovarian cancer (n = 1), thyroid malignant neoplasm (n = 1), meningioma (n = 1). Variants most frequently involved <italic toggle="yes">BRCA1, BRCA2, MUTYH, CHEK2, PALB2</italic>, and <italic toggle="yes">MSH6.</italic> Among 14 MINAS patients, common gene combinations included <italic toggle="yes">BRCA1+MUTYH</italic> and <italic toggle="yes">CHEK2+PALB2</italic>.</p><p>As this study involves sensitive patient data, the datasets are not deposited in public repositories. The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This study presents the first comprehensive evaluation of MINAS in a Turkish hereditary cancer cohort and contributes to the growing recognition that multilocus germline mutations are not rare among genetically predisposed individuals (<xref rid="B12" ref-type="bibr">Schrader et al., 2016</xref>; <xref rid="B13" ref-type="bibr">Whitworth et al., 2016</xref>; <xref rid="B15" ref-type="bibr">Agaoglu et al., 2024</xref>). We observed a MINAS prevalence of 2.1% in the overall cohort and 8.2% among mutation-positive patients, in line with previously reported rates ranging from 0.5% to 3%.</p><p>The coexistence of pathogenic variants in distinct cancer susceptibility genes may affect disease onset, spectrum, and progression. In our study, multiple MINAS patients developed cancer before the age of 50, and some exhibited tumor types associated with both mutated genes&#8212;such as the combination of <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">MUTYH</italic>, suggesting additive or synergistic effects (<xref rid="B10" ref-type="bibr">El Tekle et al., 2021</xref>). With respect to recessive genes such as MUTYH, we agree that the role of monoallelic carriers is still debated. However, consistent with prior literature, we have included these variants when they co-occurred with a second pathogenic variant in a definitive cancer susceptibility gene, as such cases may still contribute to understanding the broader phenotypic spectrum of MINAS.</p><p>Genetic counseling for MINAS remains challenging. Pedigree analysis often fails to capture the complexity of multilocus inheritance, and risk stratification may be incomplete without multigene panel testing (<xref rid="B11" ref-type="bibr">Bednar et al., 2024</xref>; <xref rid="B4" ref-type="bibr">Hampel et al., 2015</xref>). Current clinical guidelines primarily focus on monogenic inheritance models (e.g., <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">TP53</italic>), and do not yet fully address how to manage individuals with multiple LP/P variants. Developing risk-adapted surveillance and preventive care strategies for such cases should be a priority for expert panels such as NCCN and ESMO.</p><p>Therapeutically, MINAS cases may open novel windows of opportunity. For example, individuals with homologous recombination deficiency (HRD) due to <italic toggle="yes">BRCA</italic> mutations may benefit from PARP inhibitors (<xref rid="B8" ref-type="bibr">Mirza et al., 2016</xref>), while coexisting mismatch repair (MMR) deficiency (e.g., <italic toggle="yes">MSH2</italic>, <italic toggle="yes">PMS2</italic>) may make them eligible for immunotherapy (<xref rid="B6" ref-type="bibr">Le et al., 2017</xref>). The biological consequences of these combinatorial genotypes remain underexplored, but preclinical modeling&#8212;especially through organoid-based systems&#8212;may help illuminate these interactions (<xref rid="B2" ref-type="bibr">Drost and Clevers, 2018</xref>).</p><p>The clinical case involving an <italic toggle="yes">ATM</italic>-<italic toggle="yes">MITF</italic> dual variant carrier identified during segregation analysis further emphasizes the diagnostic power of multigene testing. In this context, large panel-based approaches not only enhance mutation detection rates but also generate clinically meaningful insights (<xref rid="B7" ref-type="bibr">Mandelker et al., 2019</xref>), particularly in genetically heterogeneous populations like Turkey (<xref rid="B5" ref-type="bibr">Ates et al., 2022</xref>).</p><p>A key limitation of this study is its retrospective design and reliance on available clinical data for phenotype-genotype correlation. Moreover, segregation analysis and functional assays were not conducted, which limits inference on variant expressivity and penetrance (<xref rid="B9" ref-type="bibr">Kingdom and Wright, 2022</xref>).</p><p>In cases of MINAS (Multilocus Inherited Neoplasia Allele Syndrome), clinical follow-up, preventive strategies, and surveillance are often more challenging due to the presence of pathogenic variants in two distinct cancer predisposition genes. This complexity arises from the fact that the penetrance, cancer spectrum, and tissue/organ specificity associated with each gene can differ significantly. As a result, it is often unclear whether a malignancy observed in a patient originates primarily from one gene, or represents a synergistic effect of both variants&#8212;with uncertainty regarding which gene exerts a dominant influence. Therefore, detailed family segregation analysis and phenotypic assessment of other family members are critically important&#8212;not only for the follow-up of the index case but also for the clinical management of other MINAS carriers or monoallelic mutation carriers within the family.</p><p>In summary, MINAS represents a distinct and clinically relevant subgroup of hereditary cancer syndromes. As precision oncology advances, dedicated efforts are needed to understand the biological and clinical implications of multilocus germline variation and to design personalized management strategies accordingly.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>Our study expands the clinical and genomic landscape of MINAS by characterizing its prevalence, gene combinations, and tumor phenotypes in a Turkish hereditary cancer cohort. The detection of MINAS in 2.1% of tested individuals highlights the utility of multigene panel testing in uncovering complex germline architectures. Recognizing and systematically evaluating MINAS is essential for advancing precision prevention (<xref rid="B3" ref-type="bibr">McGuigan et al., 2022</xref>), risk counseling, and tailored surveillance strategies in hereditary cancer care.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the staff of the MedRoyal Genetic Laboratory and clinical teams at Memorial Hospitals for their support in patient recruitment and data collection.</p></ack><fn-group><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/27488/overview" ext-link-type="uri">Robert Clarke</ext-link>, University of Minnesota Twin Cities, United States</p></fn><fn fn-type="reviewed-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/628885/overview" ext-link-type="uri">Raymond H. Kim</ext-link>, University of Toronto, Canada</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2290697/overview" ext-link-type="uri">Ibrahim Sahin</ext-link>, Arabian Gulf University, Bahrain</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3147943/overview" ext-link-type="uri">Mehmet Ali Ergun</ext-link>, Gazi University, T&#252;rkiye</p></fn></fn-group><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are publicly available. This data can be found here: NCBI repository, accession number PRJNA1390191.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by Antalya Memorial Hospital Ethics Committee (Decision No: 06, Date: 18.06.2025). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants&#8217; legal guardians/next of kin because Since all data were de-identified and used retrospectively, individual informed consent was not required according to institutional policy.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>TB: Conceptualization, Investigation, Methodology, Supervision, Validation, Writing &#8211; original draft, Writing &#8211; review and editing, Data curation, Formal Analysis. SS: Data curation, Formal Analysis, Software, Writing &#8211; original draft, Writing &#8211; review and editing. KH: Writing &#8211; review and editing, Investigation, Resources. UD: Investigation, Resources, Writing &#8211; review and editing. IB: Investigation, Resources, Writing &#8211; review and editing. SB: Investigation, Resources, Writing &#8211; review and editing. MeO: Investigation, Resources, Writing &#8211; review and editing. FA: Investigation, Resources, Writing &#8211; review and editing. SK: Investigation, Resources, Writing &#8211; review and editing. KP: Investigation, Resources, Writing &#8211; review and editing. NS: Investigation, Resources, Writing &#8211; review and editing. MT: Investigation, Resources, Writing &#8211; review and editing. HH: Investigation, Resources, Writing &#8211; review and editing. EN: Investigation, Resources, Writing &#8211; review and editing. AK: Investigation, Resources, Writing &#8211; review and editing. MU: Investigation, Resources, Writing &#8211; review and editing. MI: Investigation, Resources, Writing &#8211; review and editing. CE: Investigation, Resources, Writing &#8211; review and editing. NK: Investigation, Resources, Writing &#8211; review and editing. KO: Investigation, Resources, Writing &#8211; review and editing. HK: Investigation, Resources, Writing &#8211; review and editing. ED: Investigation, Resources, Writing &#8211; review and editing. VB: Investigation, Resources, Writing &#8211; review and editing. AE: Investigation, Resources, Writing &#8211; review and editing. MuO: Investigation, Resources, Writing &#8211; review and editing, Conceptualization, Supervision.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agaoglu</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Bychkovsky</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Horton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Polfus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carraway</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Cancer burden in individuals with single versus double pathogenic variants in cancer susceptibility genes</article-title>. <source>Genetics in Medicine Open</source><volume>2</volume>, <fpage>101829</fpage>. <pub-id pub-id-type="doi">10.1016/j.gimo.2024.101829</pub-id><pub-id pub-id-type="pmid">39669588</pub-id><pub-id pub-id-type="pmcid">PMC11613565</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ates</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Turkyilmaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alavanda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yildirim</surname><given-names>O.</given-names></name><name name-style="western"><surname>Guney</surname><given-names>A. I.</given-names></name></person-group> (<year>2022</year>). <article-title>Multigene panel testing in Turkish hereditary cancer syndrome patients</article-title>. <source>Medeni Med. J.</source><volume>37</volume> (<issue>2</issue>), <fpage>150</fpage>&#8211;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.4274/MMJ.galenos.2022.22556</pub-id><pub-id pub-id-type="pmid">35734982</pub-id><pub-id pub-id-type="pmcid">PMC9234359</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bednar</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Rauh-Hain</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>de Aguinaga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Peral</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Experiences of family communication and cascade genetic testing for Hereditary cancer in medically Underserved populations-a qualitative study</article-title>. <source>Cancer Prev. Res. (Phila)</source><volume>17</volume> (<issue>1</issue>), <fpage>19</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-23-0303</pub-id><pub-id pub-id-type="pmid">37913800</pub-id><pub-id pub-id-type="pmcid">PMC10872900</pub-id></mixed-citation></ref><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couch</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Toland</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Miron</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer</article-title>. <source>J. Clin. Oncol.</source><volume>33</volume> (<issue>4</issue>), <fpage>304</fpage>&#8211;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2014.57.1414</pub-id><pub-id pub-id-type="pmid">25452441</pub-id><pub-id pub-id-type="pmcid">PMC4302212</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drost</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clevers</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>Organoids in cancer research</article-title>. <source>Nat. Rev. Cancer</source><volume>18</volume> (<issue>7</issue>), <fpage>407</fpage>&#8211;<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-018-0007-6</pub-id><pub-id pub-id-type="pmid">29692415</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Tekle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bernasocchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Unni</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Bertoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us</article-title>. <source>Trends in Cancer</source><volume>7</volume> (<issue>9</issue>), <fpage>823</fpage>&#8211;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1016/j.trecan.2021.04.009</pub-id><pub-id pub-id-type="pmid">34031014</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pearlman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wiesner</surname><given-names>G. L.</given-names></name></person-group> (<year>2015</year>). <article-title>A practice guideline from the American college of medical genetics and genomics and the national society of genetic counselors: referral indications for cancer predisposition assessment</article-title>. <source>Genet. Med.</source><volume>17</volume> (<issue>1</issue>), <fpage>70</fpage>&#8211;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2014.147</pub-id><pub-id pub-id-type="pmid">25394175</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kingdom</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>C. F.</given-names></name></person-group> (<year>2022</year>). <article-title>Incomplete penetrance and variable expressivity: from clinical studies to population cohorts</article-title>. <source>Front. Genet.</source><volume>13</volume>, <fpage>920390</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2022.920390</pub-id><pub-id pub-id-type="pmid">35983412</pub-id><pub-id pub-id-type="pmcid">PMC9380816</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Durham</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Aulakh</surname><given-names>L. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title>. <source>Science</source><volume>357</volume> (<issue>6349</issue>), <fpage>409</fpage>&#8211;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id><pub-id pub-id-type="pmid">28596308</pub-id><pub-id pub-id-type="pmcid">PMC5576142</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandelker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donoghue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Talukdar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bandlamudi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vivek</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group</article-title>. <source>Ann. Oncol.</source><volume>30</volume> (<issue>8</issue>), <fpage>1221</fpage>&#8211;<lpage>1231</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdz136</pub-id><pub-id pub-id-type="pmid">31050713</pub-id><pub-id pub-id-type="pmcid">PMC6683854</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuigan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whitworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andreou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hearn</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Tischkowit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>E. R.</given-names></name></person-group> (<year>2022</year>). <article-title>Multilocus inherited neoplasia allele syndrome (MINAS): an update</article-title>. <source>Eur. J. Hum. Genet.</source><volume>30</volume> (<issue>3</issue>), <fpage>265</fpage>&#8211;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-021-01013-6</pub-id><pub-id pub-id-type="pmid">34983940</pub-id><pub-id pub-id-type="pmcid">PMC8904543</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirza</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Monk</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Herrstedt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oza</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Mahner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Redondo</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer</article-title>. <source>N. Engl. J. Med.</source><volume>375</volume> (<issue>22</issue>), <fpage>2154</fpage>&#8211;<lpage>2164</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1611310</pub-id><pub-id pub-id-type="pmid">27717299</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schrader</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>V.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zehir</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Germline variants in targeted tumor sequencing using matched normal DNA</article-title>. <source>JAMA Oncol.</source><volume>2</volume> (<issue>1</issue>), <fpage>104</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.5208</pub-id><pub-id pub-id-type="pmid">26556299</pub-id><pub-id pub-id-type="pmcid">PMC5477989</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tung</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>N. U.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wenstrup</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer</article-title>. <source>J. Clin. Oncol.</source><volume>34</volume> (<issue>13</issue>), <fpage>1460</fpage>&#8211;<lpage>1468</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2015.65.0747</pub-id><pub-id pub-id-type="pmid">26976419</pub-id><pub-id pub-id-type="pmcid">PMC4872307</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Skytte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sunde</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Arends</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Happerfield</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Multilocus inherited neoplasia alleles syndrome: a case series and review</article-title>. <source>JAMA Oncol.</source><volume>2</volume> (<issue>3</issue>), <fpage>373</fpage>&#8211;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.4771</pub-id><pub-id pub-id-type="pmid">26659639</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>